Opinion|Videos|January 16, 2026
The Role of Elacestrant in ER+/HER2– Advanced Breast Cancer Harboring ESR1 Mutations
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.
Advertisement
Episodes in this series
Hope S. Rugo, MD, and Seth Wander, MD, PhD, explore the clinical role of elacestrant (Orserdu) in estrogen receptor/HER2-negative advanced breast cancer with ESR1 mutations following the agent’s January 2023 FDA approval for use in patients with disease progression following at least 1 line of endocrine therapy. They discuss how this oral SERD addresses endocrine resistance and fits into current treatment algorithms. Rugo and Wander place elacestrant’s activity in context of evolving post-CDK4/6 inhibitor therapeutic options.
Advertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
Weekly oral dordaviprone maintenance after allogeneic transplant produced no DLTs and low rates of grade 3/4 cytopenias in high-risk AML and MDS.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
4
NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma
5